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Age-targeted tuberculosis vaccination in China and 
implications for vaccine development: a modelling study
Rebecca C Harris, Tom Sumner, Gwenan M Knight, Tom Evans, Vicky Cardenas, Chen Chen, Richard G White
Summary
Background Tuberculosis is the leading single-pathogen cause of death worldwide, and China has the third largest 
number of cases worldwide. New tools, such as new vaccines, are needed to meet WHO tuberculosis goals. 
Tuberculosis vaccine development strategies mostly target infants or adolescents, but given China’s ageing epidemic, 
vaccinating older people might be important. We modelled the potential impact of new tuberculosis vaccines in 
China targeting adolescents (15–19 years) or older adults (60–64 years) with varying vaccine characteristics to inform 
strategic vaccine development.
Methods A Mycobacterium tuberculosis transmission model was calibrated to age-stratified demographic and 
epidemiological data from China. Varying scenarios of vaccine implementation (age targeting [adolescents or older 
adults] and coverage [30% or 70%]) and characteristics (efficacy [40%, 60%, or 80%], duration of protection [10 years 
or 20 years], and host infection status required for efficacy [pre-infection, post-infection in latency, post-infection in 
latency or recovered, or pre-infection and post-infection]) were assessed. Primary outcomes were tuberculosis 
incidence and mortality rate reduction in 2050 in each vaccine scenario compared with the baseline (no new vaccine) 
scenario and cumulative number needed to vaccinate (NNV) per case or death averted, 2025–50.
Findings By 2050, results suggest that 74·5% (uncertainty interval [UI] 70·2–78·6) of incident tuberculosis cases in 
China would occur in people aged 65 years or older, and 75·1% (66·8–80·7) of all cases would be due to reactivation, 
rather than new infection. All vaccine profiles delivered to older adults had higher population-level impact (reduction 
of incidence and mortality rates) and lower NNV per case and per death averted than if delivered to adolescents. For 
an intermediate vaccine scenario of 60% efficacy, 10-year protection, and 70% coverage, the reduction of tuberculosis 
incidence rates with older adult vaccination was 1·9 times (UI 1·5–2·6) to 157·5 times (119·3–225·6) greater than 
with adolescent vaccination, and the NNV was 0·011 times (0·008–0·014) to 0·796 times (0·632–0·970) lower. 
Furthermore, with older adult vaccination, post-infection vaccines provided substantially greater mortality and 
incidence rate reductions than pre-infection vaccines.
Interpretation Adolescent-targeted tuberculosis vaccines, the focus of many development plans, would have only a 
small impact in ageing, reactivation-driven epidemics such as those in China. Instead, an efficacious post-infection 
vaccine delivered to older adults will be crucial to maximise population-level impact in this setting and would provide 
an important contribution towards achieving WHO goals. Older adults should be included in tuberculosis vaccine 
clinical development and implementation planning.
Funding Aeras and UK MRC.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Despite progress in tuberculosis prevention and care 
during the past two decades,1 China remains the third 
largest contributor to the global burden of new tuberculosis 
cases, accounting for 889 000 (761 000–1 030 000) new 
cases in 2017.2 Increasing public-sector investment in 
tuberculosis care has contributed to the detection of 
87% of cases and treatment success in 94% of cases.1,2 
Given the substantial achievements in the scale-up 
of existing tuberculosis care and prevention options, 
mathematical modelling suggests that gains possible 
from further investment in existing tools alone are 
unlikely to reach WHO tuberculosis goals for 2025 
(50% incidence reduction vs 2015), 2035 (90% reduction 
vs 2015), and 2050 (elimination, defined as less than 
one case per million people per year) in China.3–7 
Innovative tools, such as new tuberculosis vaccines, will 
be essential for achieving these targets.3–6
There have been increasingly rapid advances in the 
development of new tuberculosis vaccines in the past few 
years, with 12 candidates in clinical trials, including four in 
phase 2B/3.8 2018 was an important year for tuberculosis 
vaccine development, with results from two new preclinical 
studies,9 the late-stage H4 versus Bacillus Calmette–Guérin 
(BCG) revaccination10 and M72/AS01E clinical trials,11 and 
with results anticipated from the Mycobacterium vaccae 
trial (NCT01979900). Tuberculosis vaccine target product 
profiles outline the desired vaccine characteristics and 
recipient populations for new vaccines, and clinical 
development plans provide the pathway to achieving these 
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criteria. Mathematical modelling provides a systematic 
framework to explore the potential future impact of vaccine 
characteristics and implementation strategies to inform 
target product profile development. The impact achieved 
might vary by epidemiological and demographic setting,12,13 
therefore country-specific models are needed for appro-
priate vaccine selection and implementation planning, 
including age targeting. A phase 3 clinical trial of a 
prophylactic tuberculosis vaccine candidate has been 
conducted in China (NCT01979900) and therefore, mod-
elling to clarify the potential benefit of new tuberculosis 
vaccines and different implementation strategies in China 
is urgently needed.
Traditional vaccine development pathways focused on 
infant vaccination; however, in the past few years, there 
has been a shift towards adolescents and adults,14 
supported by insights from mathematical modelling.13,15 
Yet populations aged 60 years and older remain neglected 
in tuberculosis vaccine development pathways, despite 
high tuberculosis disease burden in older age groups 
in several countries with different levels of socio-
demographic development.16 Given the dramatic and 
ongoing population ageing in China,17 and higher 
prevalence of latent infection in older populations,18 a 
shift in burden to older age groups could be expected.
According to a systematic review of modelling studies 
on tuberculosis vaccines, although vaccination of infants 
has been compared with adolescents or people of all 
ages, no model explores the potential impact of new 
tuberculosis vaccines for older age groups.12 Dynamics of 
tuberculosis disease and demographics are intimately 
linked, and influence the effect of age-targeted 
interventions.13 Only two studies have modelled new 
tuberculosis vaccines in China,19,20 and neither accounted 
for age specificities in epidemiology or demographics. 
Furthermore, in these studies, vaccination was either at 
birth or all ages, and vaccine characteristics modelled 
were unclear or unrealistic (eg, 100% vaccine efficacy).19,20 
Although it did not explore vaccines, a modelling study 
in China showed that existing tuberculosis interventions 
alone would not be enough to reach WHO 2035 targets, 
whereas development of preventive therapy for adults 
aged 65 years or older could be transformational.5 We 
aimed to estimate future trends in tuberculosis epi-
demiology and the impact of new tuberculosis vaccines 
in China with varying vaccination scenarios.
Methods
Study design
This prospective modelling study assessed the effect of 
varying implementation strategies (age targeting and 
coverage) and vaccine characteristics (efficacy, duration 
of protection, and host infection status required for 
efficacy) of new tuberculosis vaccines on the tuberculosis 
epidemic in China.
Model structure and calibration
An age-stratified population-level compartmental deter- 
ministic transmission model calibrated to China’s 
tuberculosis epidemic was developed in R, based on the 
model developed by Knight and colleagues (appendix).15 
The model has five populations with different infection 
Research in context
Evidence before this study
We searched the tuberculosis vaccine epidemiological modelling 
literature up to July 19, 2017. We searched PubMed, Embase, and 
the WHO Global Health Library with the search terms (“models, 
theoretical”[mesh]) OR “mathematical model*”) AND (TB OR 
tuberculosis OR “tuberculosis”[mesh]) AND (vaccin* OR 
immuniz* OR immunis* OR “tuberculosis vaccines”[mesh]). 
Previous studies suggest that targeting new vaccines to 
adolescents would have a greater impact than infant vaccination; 
however, no previous research has explored the potential impact 
of new tuberculosis vaccines targeting older adults. Only two 
modelling studies have explored the impact of new tuberculosis 
vaccines in China, one compared vaccination at birth to all-age 
mass vaccination and one was assumed mass vaccination. 
Results suggested that mass vaccination, particularly 
post infection, might be important for elimination in China. 
However, crucially, age specificity in demographic and epidemic 
dynamics in China has not been addressed in vaccine models.
Added value of this study
To the best of our knowledge, our research is the first to assess 
the potential effect of new tuberculosis vaccines targeting older 
adults (aged 60–64 years) and to compare this approach with 
adolescent vaccination, which is the age group that most 
vaccination strategies have focused on. This data-driven model is 
calibrated to age-stratified data from WHO and the UN 
population division, as well as empirical studies on tuberculosis 
demographics, prevalence, mortality, notification, and incidence, 
including temporal trends, and it incorporates empirical data on 
non-random age mixing. This study is the first to show that older 
adult vaccination with new tuberculosis vaccines is likely to be 
crucial to maximising impact in settings such as China and 
strengthens the conclusions from previous studies suggesting 
that vaccines effective post-infection will be needed in China.
Implications of all the available evidence
Although adolescent vaccination might be a suitable 
global-level strategy, important differences in country-level 
epidemiology and demography might mean that 
adolescent-targeted tuberculosis vaccines have low impact in 
ageing, reactivation-driven tuberculosis epidemics such as 
that in China. In these settings, an efficacious post-infection 
vaccine delivered to older adults will be crucial to maximise 
population-level benefits. Older adults should be included in 
tuberculosis vaccine clinical development and 
implementation planning.
See Online for appendix
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For the UN Population Division 
World Population Prospects see 
https://esa.un.org/unpd/wpp/
Download/Standard/Population/
states: uninfected, latent infection, bacteriologically 
positive active tuberculosis disease, bacteriologically 
negative active tuberculosis disease, and recovered from 
active tuberculosis disease. Transitions between states 
represent acquisition of infection; development of 
primary, reactivation, or relapse disease; effective 
detection and treatment; or natural cure (appendix). 
Neonates are assumed to be in the uninfected state at 
birth, all-cause mortality is in all states, and tuberculosis 
mortality is in active disease states. Uninfected, latent, 
and recovered states comprised both unvaccinated and 
vaccinated strata. Age was modelled in single years from 
0 to 100. Age categories for vaccine implementation were 
adolescents (15–19 years) or older adults (60–64 years).
Main age categories for parameters were children 
(0–14 years), adolescents and adults (15–64 years), and 
people aged 65 years or older. We identified age-stratified 
natural history parameter prior ranges from available 
data (appendix). Data were unavailable for immuno-
senescence in people aged 65 years or older, but HIV has 
been proposed as a proxy.21 Therefore, for parameters 
without available data for this age group, we assumed the 
lower bounds of the priors to be equal to HIV-negative 
populations and the upper bounds equal to mildly 
immunocompromised HIV-positive populations. When 
the HIV-positive and HIV-negative ranges overlapped, 
the upper bound of the prior for adults aged 65 years or 
older was equivalent to the upper bound of the HIV-
positive parameter range. We captured temporal 
evolution of the age distribution of infection and disease 
historically and prospectively by calibration to age-
stratified epidemiological and demographic data using 
age-specific natural history parameters and contact 
patterns. To provide a more gradual transition in 
reactivation, relapse, natural cure, and case detection 
parameters by age, we estimated parameters for people 
aged 55–64 years as the mean calibrated values of 
individuals aged 15–54 years and those aged 65 years 
or older. Heterogeneity in age-wise contact patterns 
was based on data from a study in southern China.22 
Treatment success was based on historical data, and 
assumed to plateau beyond 2011 because of the high 
success rates achieved (95%).23 Case detection followed a 
generalised logistic function based on WHO 1990–2010 
data.23 BCG delivery was assumed to remain constant, 
so was not explicitly modelled.
We used a two-stage calibration process. The first 
stage was a manual calibration to UN 2010 and 2050 
age-stratified demographic data and projections. The 
second stage used a method based on adaptive rejection 
approximate Bayesian computation (ABC)-Markov chain 
Monte Carlo (MCMC) using the easyABC package, 
modified to accept seed parameter values, to calibrate to 
historical epidemiological data (appendix).24 To provide 
the temporal and age-stratified granularity required, 
we calibrated the model to 18 epidemiological data 
ranges: China’s bacteriologically positive prevalence rates 
(ages ≥15, 15–29, 30–59, and ≥60 years) in 2000 and 2010,1 
2010 notification rates (all-age and ages 0–14, 15–54, 55–64, 
and ≥65 years),25 2010 mortality rates (all-age and ages 
0–14, 15–59, and ≥60 years),26 and 2010 all-age incidence.23 
We first identified potential starting points for the MCMC 
chains from the 20 highest likelihood parameter sets 
from 1 million samples randomly selected from uniform 
priors, assuming the data were independently normally 
dis tributed. Because the underlying distributions of the 
data are unclear, in particular for the WHO-estimated 
incidence, we then used an ABC-based approach. We ran 
a series of ABC-MCMC chains seeding with acceptances 
from the previous chains and adapting the acceptance 
criterion iteratively from 13 datapoints to 18 datapoints 
until a full model fit to all 18 data ranges was achieved. 
Results and uncertainty intervals (UIs; defined as 
maximum and minimum values of outcomes from the 
1000 model runs) were based on 1000 parameter sets 
randomly selected from the acceptances in the final set of 
ABC-MCMC runs.
Vaccine characteristics and implementation
We created 96 vaccine scenarios using combinations of 
two implementation characteristics (age targeting and 
coverage) and three vaccine characteristics (vaccine 
efficacy, host infection status required for efficacy, and 
duration of protection).
We explored two age-targeting scenarios: vaccination of 
adolescents (aged 15–19 years) and vaccination of older 
adults (60–64 years), implemented in 2025–50. In these 
scenarios, routine vaccination would be provided 
annually throughout this period to people aged 15 years 
or 60 years. Initial catch-up campaigns would be done in 
2025–27 for people aged 16–19 years or 61–64 years.
We explored routine vaccine coverage of 30% and 
70% of the target populations. Only people with active 
disease would be excluded from vaccination. We assumed 
annual coverage for catch-up campaigns to be a third of 
routine coverage. We assumed that there was no 
screening for latent infection before vaccination, but that 
each vaccine was only effective in the specified host 
infection status groups. Therefore, the proportion of 
people effectively immunised in a given year would be 
the product of coverage in hosts with the specified 
infection status and vaccine efficacy.
Vaccine efficacy was modelled as 40%, 60%, and 
80% protective against development of tuberculosis 
disease (prevention of disease), based on expert opinion. 
Vaccination was modelled as all or nothing protection. 
We assessed vaccine protection with the following four host 
infection statuses: (1) uninfected individuals (pre-
infection); (2) latently infected individuals (post-infection, 
latency only [PSI-L]): (3) individuals either latently infected 
or recovered from active disease (post-infection, latency 
and recovered [PSI-LR]): or (4) indi viduals either un-
infected, latently infected, or recovered from active disease 
(pre-infection and post-infection [PPI]).
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The rate of vaccine waning was set so that the duration 
of vaccine protection was normally distributed with a 
mean of 10 years (SD 1) or 20 years (2). Modelled 
durations were based on expert opinion and the estimated 
duration of protection of neonatal BCG.27 Waning 
returned the population to the equivalent unvaccinated 
state. To account for immunosenescence, an additional 
2% annual waning was assumed for populations aged 
65 years or older and was varied between 0% and 5% in 
sensitivity analyses.
All combinations of these characteristics and im- 
plementation strategies were explored. For reporting of 
some outcomes, an intermediate vaccination scenario 
was defined as 60% vaccine efficacy, 10-year protection, 
and 70% coverage. In primary analyses, vaccine 
characteristics were assumed unchanged by vaccination 
age, except immunosenescence in people aged 65 years 
or older. In sensitivity analyses, a high vaccination 
scenario vaccinating adolescents (aged 15–19 years) with 
70% coverage, 80% efficacy, and 20 years of protection 
was compared with a low vaccination scenario vaccinating 
older adults (aged 60–64 years) with 30% coverage, 
40% efficacy, and 10 years of protection.
Outcomes
We calculated epidemiological outcomes annually for 
2000–50 in the baseline (no new vaccine) scenario. We 
calculated contribution by age group to annual incident 
cases as the proportion of total incident cases arising 
from a given age group. We annually estimated the 
proportion of incident disease due to new transmission 
versus reactivation. We estimated the population-
attributable fraction (PAF) of each age group to annual 
Mycobacterium tuberculosis infections using methods 
described previously.28 We estimated prevalence of latent 
infection by age for comparison to empirical data.18
Primary outcomes were the percentage tuberculosis 
incidence and mortality rate reduction in each vaccination 
scenario compared with the no new vaccine baseline in 
2050. Secondary outcomes were cumulative number of 
tuberculosis cases or deaths averted in 2025–50 compared 
with baseline, and the cumulative number needed to 
vaccinate (NNV) per case or death averted in 2025–50. 
These outcomes were compared by age targeting and 
other vaccine characteristics.
Role of the funding source
The funder of the study was involved in development of 
the research question and commenting on the draft 
manuscript, but had no other role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all study data and materials and had final responsibility 
for the decision to submit for publication.
Results
The model fitted overall and age-stratified data for 
demography and tuberculosis prevalence, notification, 
incidence, and mortality rates (figure 1; appendix). 
Modelled all-age infection prevalence was 15·7% (UI 
12·8–18·7) in 2013, increasing almost linearly from 
1·3% (1·0–1·6) in children aged 5–9 years to 37·0% 
(31·1–42·6) in people aged 70 years or older (appendix). 
Although not calibrated to these data, modelled age-
stratified infection prevalence aligned closely with 
published QuantiFERON data.18 At vaccine introduction, 
2·2% (1·7–2·8) of people in the 15–19 years age group 
and 25·3% (20·5–30·2) of those in the 60–64 years age 
group were latently infected.
Between 2000 and 2050, a substantial shift was projected 
in the age distribution of incident tuberculosis cases, from 
75·8% (UI 71·3–81·0) in adolescents and adults aged 
15–64 years in 2000 to 74·5% (70·2–78·6) in those aged 
65 years or older in 2050 (figure 2). A concurrent age shift 
occurred in the PAFs of new infections (figure 3; 
appendix). Between 2000 and 2050, the model predicted a 
transition from an epidemic driven by new infections to 
one driven by reactivation. Between 2000 and 2025, the 
estimated proportion of incident disease due to 
reactivation rose from 28·6% (UI 21·9–32·5) to 60·1% 
(51·1–64·9). By 2050, 75·1% (66·8–80·7) of all incident 
Figure 1: Tuberculosis prevalence, 2000–50
Modelled (lines and shading) and survey-based empirical data (points and vertical bars)1 for microbiologically 
positive tuberculosis prevalence by age group. Shaded areas and vertical bars show uncertainty intervals. For 
calibration to other epidemiological and demographic calibration targets, see appendix.
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disease cases were estimated to derive from reactivation 
(figure 4), although the proportion due to reactivation was 
lower in people aged 15–19 years (6·1%; UI 4·8–7·8) than 
in those aged 60–64 years (78·1%; 71·8–81·8; appendix).
In the baseline scenario, the all-age tuberculosis 
disease incidence rate was projected to decline from 
56·2 per 100 000 population per year (UI 51·4–60·0) in 
2025 to 33·7 per 100 000 population per year (27·6–38·8) 
in 2050, and the mortality rate from 2·0 per 100 000 
population per year (1·2–3·4) in 2025 to 1·1 per 100 000 
population per year (0·6–2·2) in 2050 (appendix).
All vaccine profiles explored provided a greater 
population-level reduction of tuberculosis incidence rate 
when delivered to older adults than to adolescents 
(figure 5). With the intermediate vaccine profile, 
vaccination of older adults aged 60–64 years reduced the 
population-level incidence by 1·9 times (UI 1·5–2·6) in 
the pre-infection vaccination scenario up to 157·5 times 
(119·3–225·6) in the post-infection (PSI-LR) vaccination 
scenario compared with equivalent vaccination of adol-
escents aged 15–19 years (table). For the same intermediate 
profiles, the estimated median cumulative NNVs per case 
averted in 2025–50 for older adult vaccination were 
0·011 times (0·008–0·014) to 0·796 times (0·632–0·970) 
the NNV estimates for adolescent vaccination.
The relative impact of pre-infection versus post-infection 
vaccines varied by age at vaccination (figure 5). With older 
adult vaccination, the predicted reductions in tuberculosis 
incidence and mortality rates were smallest in vaccines 
given pre-infection, followed by the PSI-L, PSI-LR, and 
then PPI vaccines (figure 5; appendix). With vaccination 
of older adults, post-infection vaccines had smaller NNVs 
than corresponding pre-infection vaccine scenarios 
(appendix). For adol escent vaccination, the greatest 
reduction in incidence rate was with the PPI vaccine 
scenario, as with the older adult group; however, the pre-
infection vaccine scenario had a greater impact than both 
of the post-infection vaccine scenarios (PSI-L and PSI-LR).
The ratio of the tuberculosis incidence rate reductions 
with older adult vaccination to the reduction with 
Figure 2: Predicted percentage of incident tuberculosis cases by age and year, 
in the baseline scenario
Vertical bars are uncertainty intervals in a given age group.
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Figure 3: Predicted population attributable fraction of each age group to new 
Mycobacterium tuberculosis infections by year, in the baseline scenario
Lines are medians, shaded areas are uncertainty intervals.
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Figure 4: Predicted proportion of all annual incident disease cases due to new 
infections and reactivation by year in the baseline scenario
Lines are medians, shaded areas are uncertainty intervals.
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adolescent vaccination was smallest in the pre-infection 
vaccine scenario (1·9 [UI 1·5–2·6] with the intermediate 
vaccine profile), and greatest with the PSI-LR vaccine 
scenario (157·5 [119·3–225·6] with the intermediate 
vaccine profile).
Post-infection vaccine protection in both latent and 
recovered populations provided markedly greater 
reductions in incidence and mortality rates than 
protection only in latency (figure 5; appendix). This was 
especially important in older adult populations, where 
PSI-L vaccines provided a 44% (UI 20–89%) smaller 
incidence rate reduction than PSI-LR vaccines (figure 5).
As expected, increased vaccine efficacy, duration of 
protection or coverage led to greater incidence rate 
reductions (figure 5). The cumulative NNV per case or 
death averted declined with increasing vaccine efficacy 
and duration of protection, because additional benefit was 
gained without delivery of additional vaccines (appendix). 
Although raising coverage substantially increased 
numbers of cases averted, many more vaccine doses were 
required, so cumulative NNV increased slightly at higher 
coverages.
Of the vaccine profiles and implementation strategies 
explored, the most effective was the PPI vaccine with 
80% vaccine efficacy, 20-year protection, and 70% cov-
erage (figure 5). Delivered to older adults, this vaccine 
scenario averted 3·0 million (UI 2·5–3·5) cases during 
2025–50, whereas when delivered to adolescents only, 
502 000 (431 000–591 000) cases were averted (appendix). 
The lowest-impact vaccines averted as few as 2000 cases 
(UI 2000–3000; the PSI-L scenario with 30% coverage, 
40% efficacy, and 10-year duration delivered to adol-
escents) during 2025–50.
We did a sensitivity analysis comparing high 
coverage (70%), efficacy (80%), and duration of protection 
(20 years) in adolescents versus low coverage (30%), 
efficacy (40%), and duration (10 years) in older adults. 
The two post-infection vaccine scenarios still averted 
more cases when targeting older adults than when 
targeting adolescents, whereas the pre-infection scenario 
averted more cases with adolescent vaccination than 
older adult vaccination. The PPI vaccine averted similar 
numbers of cases when targeting older adults (489 000 
[UI 418 000–566 000]) to when targeting adolescents 
(502 000 [431 000–591 000]), but older adult vaccination 
still led to a lower NNV per case averted (332 [286–387]) 
than adolescents (632 [537–737]; appendix).
Figure 5: Predicted population-level impact of vaccine scenarios on 
tuberculosis incidence rate in 2050 compared with the no new vaccine 
scenario
Vaccination was implemented in 2025–50. Adolescent vaccination was 
delivered routinely to people aged 15 years during 2025–50, with a 3-year 
catch-up campaign in people aged 16–19 years in 2025–27. Older adult 
vaccination was delivered to people aged 60 years, with a 3-year catch-up 
campaign in people aged 61–64 years in 2025–27.
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Immunosenescent waning assumptions had minimal 
effect on the primary outcome. Increasing annual 
immunosenescent waning from 2% to 5% reduced the 
intermediate vaccine incidence rate reduction from 
13·8% to 12·9%. Conversely, assuming no immuno-
senescence increased this estimate to 14·4%.
Discussion
In 2025–50, all vaccine profiles explored in China 
provided higher population-level impact on incidence 
and mortality rates and lower cumulative NNV per 
case or death averted when delivered to older adults 
(60–64 years) than adolescents (15–19 years). By 2050, 
the no new vaccine baseline results suggest that about 
75·1% of incident tuberculosis cases would be due to 
reactivation of existing infections rather than new 
infections, and 74·5% of incident cases would occur in 
people aged 65 years or older. Vaccination of older adults 
with post-infection vaccines provided much greater 
reductions in tuberculosis incidence and mortality rates 
than pre-infection vaccines. Adolescent vaccination 
provided only a small benefit in terms of these outcomes. 
Thus, the inclusion of older adults in clinical trials will be 
imperative for vaccine development strategy in China 
and similar settings.
In the no new vaccine baseline scenario, transition 
from a transmission-driven epidemic mostly in adol-
escents and adults aged 15–64 years to a reactivation-
driven epidemic mostly in people aged 65 years and older 
was predicted to occur before a new vaccine is likely to be 
launched, because of population ageing and reduced 
transmission resulting from improved tuberculosis 
diagnosis, care, and prevention.
Even though immunosenescence did reduce the impact 
of older adult vaccination, targeting older adults 
consistently provided greater impact than targeting 
adolescents with equivalent vaccine scenarios. Although 
the larger size of the older adult population required 
more vaccines than adolescent campaigns with equivalent 
percentage coverage, the NNV per case averted was 
lower, often considerably, for older adult than for 
adol escent vaccination, suggesting that cost-effectiveness 
calculations might also support older adult vaccination 
strategies. Even if lower coverage was assumed for older 
adult campaigns (30%) than school-based adolescent 
campaigns (70%), PPI vaccines targeting older adults 
would still be likely to provide at least equivalent, if not 
greater, impact than adolescent vaccination.
The relative impact of pre-infection versus post-
infection vaccines on tuberculosis incidence and mortality 
rates varied between adolescent and older adult 
populations. Vaccination of older adults achieved higher 
population-level impact with post-infection vaccines, 
whereas greater impact was achieved by pre-infection 
vaccines targeting adolescents. This finding is explained 
by the substantially higher prevalence of latent infection 
in older adults. Pre-infection vaccines provided similarly 
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low population-level impact whether vaccinating 
adolescents or older adults. Post-infection vaccines 
delivered to older adults will be central to achieving the 
greatest possible impact. However, post-infection vaccines 
would have negligible impact if delivered to adolescents. 
Post-infection vaccines that are effective in both latent 
and recovered populations provided greater impact than 
those effective in latency only, particularly when delivered 
to older adults, indicating that vaccines that are also 
effective against relapse after recovery from active disease 
could have important additional value. The vaccine that is 
effective both pre-infection and post-infection provided 
the greatest impact when delivered to both age groups, 
and would be the ideal candidate for development, but at 
a minimum, a post-infection vaccine suitable for older 
adult vaccination should be developed for tuberculosis 
prevention in China if the highest population-level impact 
before 2050 is the primary goal.
Although herpes zoster vaccine trials provide proof of 
concept for achieving robust efficacy and immunogenicity 
in older age groups,29 efficacy or duration of protection 
could conceivably be compromised with age. Our results 
show that for post-infection vaccines or PPI vaccines, 
older adult vaccination would be recommended even with 
substantially lower efficacy, duration, and coverage than 
observed in adolescents. Therefore, clinical trial data to 
support vaccine registration in older populations will be 
vital. For pre-infection-only vaccines, the preference for 
vaccinating older adults would be diminished or negated 
if vaccine characteristics and coverage were substantially 
worse in older adults than in adolescents. Therefore, age-
stratified estimates of efficacy from clinical trials in pre-
infection populations will be important for designing 
impact-maximising implementation strategies. All of 
these sensitivity analysis results further strengthen our 
recommendation that older adults should be included in 
clinical trials.
With the vaccine profiles and delivery strategies 
explored, up to a 32% reduction in tuberculosis incidence 
rates could be achieved in 2050, which would be a 
substantial contribution towards WHO 2050 goals. Even 
greater benefits could be achieved with less-conservative 
delivery strategies (eg, one-off mass vaccination to all 
adults) or if higher efficacy or duration of protection were 
achieved. Our model shows that an appropriately 
designed and delivered new tuberculosis vaccine could 
substantially contribute to tuberculosis prevention in 
China.
This study had several limitations. Data were scarce for 
tuberculosis natural history parameters for people aged 
65 years or older. We represented this uncertainty in the 
calibration process by sampling from wide parameter 
priors in this age group, combining HIV-negative and 
HIV-positive adult ranges. Future secular changes in 
excluded risk factors might affect the projected baseline 
trends and absolute changes in incidence and mortality 
rates, but the projected relative impact would be expected 
to be robust to these changes. Given population ageing, 
the assumption that the contact matrix remained 
constant throughout the study period might provide 
conservative effect estimates. The probable under-
reporting of the number of contacts in the study 
informing the contact matrix was accounted for by a 
scaling factor; however, this might not have completely 
accounted for under-reporting. HIV co-infection was not 
modelled because estimates suggest that less than 1% of 
patients with tuberculosis in China are co-infected with 
HIV.2,30 Urbanisation, migrants, and gender might affect 
tuberculosis transmission and vaccine coverage, and 
might be important to consider in vaccine targeting, but 
were beyond the scope of our research question. The 
vaccine was assumed to provide all or nothing protection, 
but the alternative leaky assumption could reduce effect 
estimates.31
Because of high treatment success and case detection 
during calibration years, these were assumed to plateau 
after the calibration period. Potential future policy 
changes are challenging to predict, but if improvements 
in care measures (eg, mass active case finding) were 
achieved, or better diagnostics or treatments introduced, 
the impact achieved by vaccines could potentially be 
reduced. However, this would not affect conclusions with 
respect to age targeting, unless such an intervention 
varied in effectiveness by age. Preventive therapy for 
people aged 65 years or older was not included as a future 
intervention in this study, but comparison of the relative 
impact and cost-effectiveness of vaccines versus 
preventive therapy in this age group could provide an 
interesting avenue for future research.
Outcomes were assessed up to 2050 to align with the 
WHO 2050 elimination goal, so results are specific to 
2025–50. Full benefit of vaccines delivered before 2050 
would extend beyond 2050, therefore relative vaccine 
impact might change over longer time periods.12 Better 
vaccines (eg, lifelong protection) or coverage could 
improve impact,19 but were not considered likely scenarios 
by experts. Heterogeneity within the adult population 
could affect efficacy; variable efficacy by infection 
status was explored here, but when more is understood 
about a candidate’s mechanism of action, future studies 
could examine other population heterogeneity. Infant 
vaccination could be explored, but the impact would be 
very low over this time period given the decreasing force 
of infection in China.13,15 To answer the research question, 
we deliberately restricted mass campaigns to narrow age 
ranges (15–19 years and 60–64 years). If a new efficacious 
vaccine became available, broader campaigns could be 
implemented to increase overall benefits but would not 
affect our overall conclusions.
The results of this study are specific to the tuberculosis 
epidemic and demographics in China, but they might 
also be relevant to other countries with ageing pop-
ulations and improvements in tuberculosis control 
leading to reactivation-driven epidemics.
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This study is the first to assess the potential impact of 
new tuberculosis vaccines targeting older adults and 
to provide a comparison with adolescent vaccination, 
which has been a strategic focus over the past 5–10 years.14 
Our analysis required age-specific model parameter-
isation and calibration, and is the first China tuberculosis 
model to calibrate age-stratified mortality and notification 
rates and include data-informed non-random mixing 
by age. Our results are consistent with the conclusions 
of the study by Dye and colleagues19 regarding the 
importance of post-infection vaccines in China, but 
provide a crucial clarification: that population-level impact 
with such vaccines might be contingent on delivery to 
older age groups. These results build on the study by 
Huynh and colleagues,5 which showed the importance of 
controlling reactivation disease in people aged 65 years or 
older. Our results extend previous studies that suggested 
that adolescent and adult campaigns would have a greater 
benefit than infant vaccination,13,15,20 and we develop the 
argument further by showing that in an epidemic in an 
ageing population, the greatest benefit could be achieved 
by targeting older adults, potentially minimising the 
resources required per case averted.
Adolescent-targeted vaccines, the focus of development 
strategy for the past 5–10 years, would have only a small 
impact in ageing, reactivation-driven tuberculosis epi-
demics such as that in China. In these settings, an 
efficacious post-infection vaccine delivered to older adults 
will be crucial to maximise population-level impact and 
would provide a necessary contribution towards achieving 
the WHO 2050 tuberculosis goals. In conclusion, older 
adults should be included in tuberculosis vaccine clinical 
development and implementation planning.
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